PLC CE-marks next-generation TMR (transmyocardial revascularisation) laser:
This article was originally published in Clinica
PLC Medical Systems has CE-marked for sale in Europe its next-generation CO2 laser for transmyocardial revascularisation (TMR). The new product is less than half the weight of the company's first-generation laser allowing it to be moved more easily between surgical suites, and enabling cardiac surgeons to decide intra-operatively whether to use the device to treat area of the myocardium not addressed by bypass surgery. The Franklin, Massachusetts company has already received approval to sell the device in the US, where it will be distributed by Edwards LifeSciences (see Clinica No 949, p 18).
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.